The NEJ009 study [42] compared first-line treatment with gefitinib with or without chemotherapy for metastatic NSCLC with EGFR mutations, and the results showed that the combination group had a higher ORR and better PFS than the gefitinib group (p < 0.001). Here, EGFR is linked to non-small cell lung carcinoma.